Added to YB: 2020-12-15
Pitch date: 2020-12-15
INVA [bullish]
Innoviva, Inc.
+89.71%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI.
Market Cap
$1.6B
Pitch Price
$11.76
Price Target
N/A
Dividend
N/A
EV/EBITDA
7.03
P/E
3.92
EV/Sales
3.25
Sector
Pharmaceuticals
Category
N/A
Show full summary:
INNOVIVA INC INVA
A summary for this pitch has not been created yet.
Read full article (0 min)